Health Canada drug identification number

DIN 02455978 — DARZALEX 400 MG

DARZALEX is a solution of Daratumumab marketed by JANSSEN INC. The full Daratumumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.

DIN
02455978
Brand name
DARZALEX
Active ingredient
Daratumumab
Strength
400 MG
Dosage form
SOLUTION
Route
INTRAVENOUS
Manufacturer
JANSSEN INC
Health Canada status
MARKETED
Drug class
CD38-directed monoclonal antibody (antineoplastic)

Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.

Other Daratumumab products

DINBrandStrengthFormManufacturerStatus
02455951 DARZALEX 100 MG SOLUTION JANSSEN INC MARKETED
02502712 DARZALEX SC 1800 MG SOLUTION JANSSEN INC MARKETED

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.